On the public citation graph

Novel bronchodilators for the treatment of chronic obstructive pulmonary disease

0 signed · 150 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/med.20158openalex-snapshot
Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists
inferredcites →https://doi.org/10.1007/s10928-010-9180-2openalex-snapshot
Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients
inferredcites →https://doi.org/10.1016/j.ejphar.2003.10.027openalex-snapshot
Role of Rho-kinase in maintaining airway smooth muscle contractile phenotype
inferredcites →https://doi.org/10.1016/j.ejphar.2011.02.024openalex-snapshot
Pharmacodynamic and pharmacokinetic profile of RBx 343E48F0: A novel, long acting muscarinic receptor antagonist
inferredcites →https://doi.org/10.1016/j.ejps.2010.01.004openalex-snapshot
Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: In vitro plasma inactivation and pharmacological activity of its main metabolites
inferredcites →https://doi.org/10.1016/j.jaci.2006.02.045openalex-snapshot
Are phosphodiesterase 4 inhibitors just more theophylline?
inferredcites →https://doi.org/10.1016/j.pupt.2009.04.005openalex-snapshot
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi
inferredcites →https://doi.org/10.1016/j.pupt.2010.04.002openalex-snapshot
Doxofylline: A “Novofylline”
inferredcites →https://doi.org/10.1016/j.pupt.2010.04.005openalex-snapshot
Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
inferredcites →https://doi.org/10.1016/j.rmed.2009.12.003openalex-snapshot
Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients
inferredcites →https://doi.org/10.1016/j.rmed.2010.04.006openalex-snapshot
Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
inferredcites →https://doi.org/10.1016/j.rmed.2010.09.006openalex-snapshot
Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs
inferredcites →https://doi.org/10.1016/s0140-6736(09)61252-6openalex-snapshot
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
inferredcites →https://doi.org/10.1016/s0140-6736(09)61255-1openalex-snapshot
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
inferredcites →https://doi.org/10.1016/s0140-6736(09)61556-7openalex-snapshot
Pricing of pneumococcal vaccines under advance market commitments
inferredcites →https://doi.org/10.1021/jm1005989openalex-snapshot
Inhalation by Design: Novel Ultra-Long-Acting β2-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup
inferredcites →https://doi.org/10.1038/bjp.2008.284openalex-snapshot
Novel long‐acting bronchodilators for COPD and asthma
inferredcites →https://doi.org/10.1038/sj.bjp.0703725openalex-snapshot
The effect of selective and non‐selective phosphodiesterase inhibitors on allergen‐ and leukotriene C4‐induced contractions in passively sensitized human airways
inferredcites →https://doi.org/10.1038/sj.bjp.0706724openalex-snapshot
Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea‐pig and human airways
inferredcites →https://doi.org/10.1080/15412550903156333openalex-snapshot
Combination of Formoterol and Tiotropium in the Treatment of COPD: Effects on Lung Function
inferredcites →https://doi.org/10.1111/j.1476-5381.2009.00170.xopenalex-snapshot
Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease
inferredcites →https://doi.org/10.1111/j.1476-5381.2011.01339.xopenalex-snapshot
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi
inferredcites →https://doi.org/10.1124/jpet.105.098251openalex-snapshot
In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action
inferredcites →https://doi.org/10.1124/jpet.107.129296openalex-snapshot
Pharmacological Characterization of Indacaterol, a Novel Once Daily Inhaled β2 Adrenoceptor Agonist, on Small Airways in Human and Rat Precision-Cut Lung Slices
inferredcites →https://doi.org/10.1124/jpet.109.151639openalex-snapshot
Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile
inferredcites →https://doi.org/10.1124/jpet.109.152470openalex-snapshot
Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs
inferredcites →https://doi.org/10.1124/jpet.110.167007openalex-snapshot
Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models
inferredcites →https://doi.org/10.1124/jpet.110.170035openalex-snapshot
Bronchodilator Activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a Potent, Long-Acting, and Selective Muscarinic M3 Receptor Antagonist
inferredcites →https://doi.org/10.1124/mol.110.069120openalex-snapshot
THRX-198321 Is a Bifunctional Muscarinic Receptor Antagonist and β2-Adrenoceptor Agonist (MABA) That Binds in a Bimodal and Multivalent Manner
inferredcites →https://doi.org/10.1136/thx.2009.125435openalex-snapshot
Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol versus twice-daily formoterol in COPD
inferredcites →https://doi.org/10.1136/thx.2010.139113openalex-snapshot
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
inferredcites →https://doi.org/10.1136/thx.54.8.730openalex-snapshot
Long acting beta 2 agonists and theophylline in stable chronic obstructive pulmonary disease
inferredcites →https://doi.org/10.1152/ajplung.00033.2003openalex-snapshot
Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function
inferredcites →https://doi.org/10.1152/ajplung.1997.273.4.l807openalex-snapshot
Regulation of cGMP by soluble and particulate guanylyl cyclases in cultured human airway smooth muscle
inferredcites →https://doi.org/10.1159/000316368openalex-snapshot
New Therapies for Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4249openalex-snapshot
GS-424020 – A Novel Mutual Prodrug Of Salmeterol And Desisobutrylciclesonide Attenuates Acute Bronchoconstriction In The Absence Of Cardiovascular Side-Effects In Ragweed Sensitized And Naïve Dogs
inferredcites →https://doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4440openalex-snapshot
Efficacy And Safety Of Aclidinium Bromide 400 µg BID Compared With Placebo And Tiotropium In Patients With Moderate To Severe COPD
inferredcites →https://doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4447openalex-snapshot
GW642444, a Novel Inhaled Long-acting Beta2 Adrenoceptor Agonist (LABA), At Single Doses Of 25, 50 And 100mcg, Is Well Tolerated And Demonstrates Prolonged Bronchodilation In COPD Patients
inferredcites →https://doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4451openalex-snapshot
In Vitro Pharmacological Characterisation Of GW642444, A Novel Long Acting ²2-agonist (LABA) Using Human Recombinant ²1/2/3 Adrenoceptor CAMP Assays
inferredcites →https://doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4453openalex-snapshot
Pharmacological Characterisation Of GW642444, A Long-acting ²2-agonist (LABA) With Rapid Onset And Long Duration, On Isolated Large And Small Human Airways
inferredcites →https://doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4457openalex-snapshot
ALKS 27 (Trospium Inhalation Powder) Improves Lung Function Following Single Administration In Subjects With COPD
inferredcites →https://doi.org/10.1164/rccm.200703-456soopenalex-snapshot
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1164/rccm.201204-0596ppopenalex-snapshot
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1165/rcmb.2007-0171ocopenalex-snapshot
A Major Functional Role for Phosphodiesterase 4D5 in Human Airway Smooth Muscle Cells
inferredcites →https://doi.org/10.1177/1753465807080740openalex-snapshot
Review: Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease
inferredcites →https://doi.org/10.1183/09031936.00013109openalex-snapshot
Emerging inhaled bronchodilators: an update
inferredcites →https://doi.org/10.1183/09031936.00032806openalex-snapshot
Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi
inferredcites →https://doi.org/10.1183/09031936.00051110openalex-snapshot
Symptom variability in patients with severe COPD: a pan-European cross-sectional study
inferredcites →https://doi.org/10.1183/09031936.00068908openalex-snapshot
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD
inferredcites →https://doi.org/10.1186/1465-9921-11-26openalex-snapshot
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
inferredcites →https://doi.org/10.1186/1465-9921-12-45openalex-snapshot
Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review
inferredcites →https://doi.org/10.1358/dot.2010.46.3.1450070openalex-snapshot
Indacaterol for chronic obstructive pulmonary disease (COPD)
inferredcites →https://doi.org/10.1378/chest.09-2363openalex-snapshot
Treatment Effects of Low-Dose Theophylline Combined With an Inhaled Corticosteroid in COPD
inferredcites →https://doi.org/10.1378/chest.119.6.1661openalex-snapshot
Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD
inferredcites →https://doi.org/10.1378/chest.129.1.5openalex-snapshot
COPD, Inflammation and Its Modulation by Phosphodiesterase 4 Inhibitors
inferredcites →https://doi.org/10.1517/13543770902815527openalex-snapshot
Which of three structures is AZD-3199?

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4855142openalex-extracted
Polygala Tenuifolia Willd Water Extract Delays the Progression of Cigarette Smoke-Induced Copd in Mice by Inhibiting Pulmonary Inflammation and Remodeling Gut Microbiota Homeostasis
inferred← citeshttps://doi.org/10.1002/prp2.46openalex-snapshot
The in vivo efficacy and side effect pharmacology of GS ‐5759, a novel bifunctional phosphodiesterase 4 inhibitor and long‐acting β2‐adrenoceptor agonist in preclinical animal species
inferred← citeshttps://doi.org/10.1007/164_2016_68openalex-snapshot
Muscarinic Receptor Antagonists
inferred← citeshttps://doi.org/10.1007/978-981-16-4392-7_1openalex-snapshot
An Introduction to Respiratory Diseases and an Emerging Need for Efficient Drug Delivery Systems
inferred← citeshttps://doi.org/10.1007/s10337-017-3244-zopenalex-snapshot
Enantiomeric Separation of (R,S)-Aclidinium Bromide with Negatively Charged Gamma-Cyclodextrin by CE
inferred← citeshttps://doi.org/10.1007/s13205-024-04051-1openalex-snapshot
Application of nano- and micro-particle-based approaches for selected bronchodilators in management of asthma
inferred← citeshttps://doi.org/10.1016/b978-0-12-396492-2.00014-xopenalex-snapshot
Bifunctional Compounds for the Treatment of COPD
inferred← citeshttps://doi.org/10.1016/b978-0-12-396493-9.00003-0openalex-snapshot
Multivalent Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) Molecules for the Treatment of COPD
inferred← citeshttps://doi.org/10.1016/j.arbr.2012.10.006openalex-snapshot
M2–β2 Interaction: A Basis for Combined Bronchodilator Treatment
inferred← citeshttps://doi.org/10.1016/j.arbres.2012.10.001openalex-snapshot
Interacción M2-β2: bases para el tratamiento broncodilatador combinado
inferred← citeshttps://doi.org/10.1016/j.bbrep.2023.101438openalex-snapshot
cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features
inferred← citeshttps://doi.org/10.1016/j.cbi.2021.109637openalex-snapshot
Nanotechnology based advanced therapeutic strategies for targeting interleukins in chronic respiratory diseases
inferred← citeshttps://doi.org/10.1016/j.cca.2013.07.031openalex-snapshot
Sports doping: Emerging designer and therapeutic β2-agonists
inferred← citeshttps://doi.org/10.1016/j.ccm.2013.10.005openalex-snapshot
Bronchodilators
inferred← citeshttps://doi.org/10.1016/j.coph.2012.02.019openalex-snapshot
New bronchodilators
inferred← citeshttps://doi.org/10.1016/j.coph.2012.03.006openalex-snapshot
Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies
inferred← citeshttps://doi.org/10.1016/j.coph.2013.03.014openalex-snapshot
New treatments for COPD
inferred← citeshttps://doi.org/10.1016/j.drudis.2013.07.005openalex-snapshot
Novel anti-cholinergics in COPD
inferred← citeshttps://doi.org/10.1016/j.ejphar.2015.04.042openalex-snapshot
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e32402openalex-snapshot
A review of the safety profile, antioxidant, anti-inflammatory, and bronchorelaxant activities of Waltheria indica Linn (Malvaceae): A potential antiasthmatic phytomedicine
inferred← citeshttps://doi.org/10.1016/j.jaci.2015.05.052openalex-snapshot
Therapeutic approaches to asthma–chronic obstructive pulmonary disease overlap syndromes
inferred← citeshttps://doi.org/10.1016/j.jct.2020.106126openalex-snapshot
The solubility profile and apparent thermodynamic analysis of doxofylline in pure and mixed solvents
inferred← citeshttps://doi.org/10.1016/j.jneuroim.2018.10.001openalex-snapshot
β-arrestin2 regulates the anti-inflammatory effects of Salmeterol in lipopolysaccharide-stimulated BV2 cells
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2016.04.002openalex-snapshot
Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones
inferred← citeshttps://doi.org/10.1016/j.pupt.2012.12.006openalex-snapshot
Long-acting muscarinic receptor antagonists for the treatment of respiratory disease
inferred← citeshttps://doi.org/10.1016/j.pupt.2015.02.007openalex-snapshot
Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD
inferred← citeshttps://doi.org/10.1016/j.pupt.2017.01.003openalex-snapshot
Which treatment for obstructive airway disease: The inhaled bronchodilators
inferred← citeshttps://doi.org/10.1016/j.pupt.2019.03.004openalex-snapshot
Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways
inferred← citeshttps://doi.org/10.1016/j.resp.2013.02.004openalex-snapshot
Immunological aspects of phosphodiesterase inhibition in the respiratory system
inferred← citeshttps://doi.org/10.1016/j.rmed.2018.10.006openalex-snapshot
Evaluation of the preference, satisfaction and correct use of Breezhaler® and Respimat® inhalers in patients with chronic obstructive pulmonary disease – INHALATOR study
inferred← citeshttps://doi.org/10.1016/j.rmed.2022.107035openalex-snapshot
The role of lung macrophages in chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1021/acsptsci.0c00127openalex-snapshot
Identification and Characterization of Novel Bronchodilator Agonists Acting at Human Airway Smooth Muscle Cell TAS2R5
inferred← citeshttps://doi.org/10.1038/nrd4025openalex-snapshot
New anti-inflammatory targets for chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1039/d0md00423eopenalex-snapshot
Pyridazinone derivatives as potential anti-inflammatory agents: synthesis and biological evaluation as PDE4 inhibitors
inferred← citeshttps://doi.org/10.1074/jbc.ra120.016056openalex-snapshot
The short third intracellular loop and cytoplasmic tail of bitter taste receptors provide functionally relevant GRK phosphorylation sites in TAS2R14
inferred← citeshttps://doi.org/10.1080/00325481.2015.1080589openalex-snapshot
Bronchodilators, receptors and cross-talk: Together is better?
inferred← citeshttps://doi.org/10.1080/03007995.2019.1654722openalex-snapshot
Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD
inferred← citeshttps://doi.org/10.1080/13543784.2019.1661990openalex-snapshot
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD
inferred← citeshttps://doi.org/10.1080/14728214.2017.1367382openalex-snapshot
Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD
inferred← citeshttps://doi.org/10.1080/17512433.2019.1587292openalex-snapshot
Revefenacin for the treatment of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1080/17512433.2024.2438187openalex-snapshot
The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1096/fj.201802627rropenalex-snapshot
Differential long‐term regulation of TAS2R14 by structurally distinct agonists
inferred← citeshttps://doi.org/10.1124/jpet.113.204644openalex-snapshot
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone
inferred← citeshttps://doi.org/10.1124/jpet.113.210997openalex-snapshot
The In Vitro Pharmacology of GS-5759, A Novel Bifunctional Phosphodiesterase 4 Inhibitor and Long Acting β2-Adrenoceptor Agonist
inferred← citeshttps://doi.org/10.1124/pr.111.004580openalex-snapshot
Pharmacology and Therapeutics of Bronchodilators
inferred← citeshttps://doi.org/10.1155/2021/1636816openalex-snapshot
Pharmacologic Activities of Plant‐Derived Natural Products on Respiratory Diseases and Inflammations
inferred← citeshttps://doi.org/10.1155/2022/5058121openalex-snapshot
Targeting COPD with PLGA‐Based Nanoparticles: Current Status and Prospects
inferred← citeshttps://doi.org/10.1159/000368986openalex-snapshot
Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium
inferred← citeshttps://doi.org/10.1159/000502261openalex-snapshot
Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies
inferred← citeshttps://doi.org/10.1164/rccm.201209-1739ppopenalex-snapshot
β2-Agonist Therapy in Lung Disease
inferred← citeshttps://doi.org/10.1177/2284240318804808openalex-snapshot
Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study
inferred← citeshttps://doi.org/10.1183/09031936.00003814openalex-snapshot
Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1183/16000617.0095-2019openalex-snapshot
The future of bronchodilation: looking for new classes of bronchodilators
inferred← citeshttps://doi.org/10.1183/20734735.014813openalex-snapshot
Long-acting bronchodilators in COPD: where are we now and where are we going?
inferred← citeshttps://doi.org/10.1186/1465-9921-14-49openalex-snapshot
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1186/2049-6958-9-64openalex-snapshot
Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium
inferred← citeshttps://doi.org/10.1186/s12906-023-04251-xopenalex-snapshot
Bei Mu Gua Lou San facilitates mucus expectoration by increasing surface area and hydration levels of airway mucus in an air-liquid-interface cell culture model of the respiratory epithelium
inferred← citeshttps://doi.org/10.1358/dot.2012.48.12.1885871openalex-snapshot
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1378/chest.14-1676openalex-snapshot
Prevention of Acute Exacerbations of COPD
inferred← citeshttps://doi.org/10.1517/13543784.2012.710602openalex-snapshot
An update on bronchodilators in Phase I and II clinical trials
inferred← citeshttps://doi.org/10.1517/14656566.2013.776539openalex-snapshot
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1517/14656566.2013.789021openalex-snapshot
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1517/14656566.2014.899581openalex-snapshot
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1517/14656566.2015.1070826openalex-snapshot
Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment
inferred← citeshttps://doi.org/10.1517/14656566.2015.983076openalex-snapshot
Indacaterol for the treatment of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1517/14728214.2012.660917openalex-snapshot
Emerging drugs for chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1586/17476348.2014.962519openalex-snapshot
Umeclidinium for the treatment of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1586/17476348.2015.986468openalex-snapshot
Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1586/17512433.2015.977256openalex-snapshot
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.18093/0869-0189-2016-26-3-267-291openalex-snapshot
Therapeutic strategy to prevent acute exacerbations of chronic obstructive pulmonary disease: clinical guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (Part 2)
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2728192/v1openalex-snapshot
Bei Mu Gua Lou San facilitates mucus expectoration by increasing surface area and hydration levels of airway mucus in an air-liquid-interface cell culture model of the respiratory epithelium
inferred← citeshttps://doi.org/10.2147/copd.s145573openalex-snapshot
Inhaled therapies in patients with moderate COPD in clinical practice: current thinking
inferred← citeshttps://doi.org/10.2147/copd.s407238openalex-snapshot
Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
inferred← citeshttps://doi.org/10.2147/copd.s85977openalex-snapshot
COPD: the patient perspective
inferred← citeshttps://doi.org/10.2147/dddt.s39449openalex-snapshot
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
inferred← citeshttps://doi.org/10.2147/jep.s242961openalex-snapshot
New Avenues for Phosphodiesterase Inhibitors in Asthma
inferred← citeshttps://doi.org/10.2147/tcrm.s84151openalex-snapshot
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
inferred← citeshttps://doi.org/10.2174/0113892002275839231205111422openalex-snapshot
Pharmacokinetics, Mass Balance, Tissue Distribution and Metabolism of [14C]101BHG-D01, a Novel Muscarinic Receptor Antagonist, in Rats
inferred← citeshttps://doi.org/10.22037/jps.v6i1.8238openalex-snapshot
Effects of opium inhalation on pulmonary volumes in smoking patients
inferred← citeshttps://doi.org/10.2478/v10201-011-0023-7openalex-snapshot
Selective Inhibition of Phosphodiesterase 7 (PDE7) by BRL50481 in Healthy and Ovalbumin-Sensitized Guinea Pigs
inferred← citeshttps://doi.org/10.2478/v10215-011-0014-6openalex-snapshot
Considering Peer Assisted Learning Methods in New Zealand's Special Needs Education Sector
inferred← citeshttps://doi.org/10.3109/15412555.2012.646587openalex-snapshot
The COPD Pipeline XIV
inferred← citeshttps://doi.org/10.33393/grhta.2018.429openalex-snapshot
Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study
inferred← citeshttps://doi.org/10.3389/fmicb.2025.1703853openalex-snapshot
Integrative network pharmacology, transcriptomics, and microbiomics elucidate the therapeutic mechanism of Polygala tenuifolia Willd water extract in chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.3390/antiox10060883openalex-snapshot
Tocotrienols: Dietary Supplements for Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.3390/ijms21030853openalex-snapshot
Lung Macrophage Functional Properties in Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.3390/ijms24054333openalex-snapshot
PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases
inferred← citeshttps://doi.org/10.3978/j.issn.2072-1439.2013.07.35openalex-snapshot
The role of indacaterol for chronic obstructive pulmonary disease (COPD).
inferred← citeshttps://doi.org/10.4081/mrm.2014.399openalex-snapshot
Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium
inferred← citeshttps://doi.org/10.4103/lungindia.lungindia_54_25openalex-snapshot
Exploring the possibility of a predictable precision therapy of COPD with inclusion of glycopyrronium responsiveness: A real-world experience
inferred← citeshttps://doi.org/10.4155/ppa-2018-0030openalex-snapshot
Ensifentrine (RPL554): an Inhaled ‘bifunctional’ Dual PDE3/4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.46691/es.v2i25.172openalex-snapshot
Eficácia e segurança do brometo de aclidínio na dpoc
inferred← citeshttps://doi.org/10.53511/pharmkaz.2023.36.74.003openalex-snapshot
ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ: ИММУНОПАТОГЕНЕЗ И ИММУНОМОДУЛИРУЮЩАЯ ТЕРАПИЯ
inferred← citeshttps://doi.org/10.6084/m9.figshare.24585939openalex-snapshot
Additional file 1 of Bei Mu Gua Lou San facilitates mucus expectoration by increasing surface area and hydration levels of airway mucus in an air-liquid-interface cell culture model of the respiratory epithelium
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.